About Index Trending news
Analyze
Pricing
Trevi Therapeutics

Trevi Therapeutics

Work at Trevi Therapeutics? Add yourself to this profile

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

20 Jul 2017
$50,500,000
Venture capital (Series C)
Omega Funds, TPG Biotechnology Partners, Aperture Venture Partners, +2

NEA leads $50.5 mln Series C round in Trevi Therapeutics

PE Hub
06 Nov 2014
$26,000,000
Venture capital (Series B)
TPG Biotech
18 Dec 2012
$6,564,102
Venture capital